DYRK inhibitor (Biosplice Therapeutics)

N/A

Report date: 2025/06/11 10:35:29
NME

Base Information

Drug NameDYRK inhibitor (Biosplice Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionDual-specificity tyrosine-phosphorylation regulated kinase 1A inhibitors
TargetsDual-specificity tyrosine-phosphorylation regulated kinase 1A
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBiosplice Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiosplice Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A